DURECT (NASDAQ:DRRX) Coverage Initiated by Analysts at StockNews.com

StockNews.com began coverage on shares of DURECT (NASDAQ:DRRX) in a report published on Thursday. The brokerage issued a sell rating on the specialty pharmaceutical company’s stock.

Separately, HC Wainwright restated a “neutral” rating on shares of DURECT in a report on Thursday, November 14th.

DURECT Stock Performance

DRRX opened at $0.80 on Thursday. The stock’s 50 day moving average price is $0.86 and its 200-day moving average price is $1.20. DURECT has a 52-week low of $0.68 and a 52-week high of $1.88. The stock has a market capitalization of $24.98 million, a PE ratio of -1.32 and a beta of 0.94.

Institutional Investors Weigh In On DURECT

An institutional investor recently raised its position in DURECT stock. Geode Capital Management LLC grew its holdings in shares of DURECT Co. (NASDAQ:DRRX) by 4.8% during the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 319,905 shares of the specialty pharmaceutical company’s stock after buying an additional 14,658 shares during the period. Geode Capital Management LLC owned 1.03% of DURECT worth $429,000 as of its most recent SEC filing. Hedge funds and other institutional investors own 28.03% of the company’s stock.

DURECT Company Profile

DURECT Corporation, a biopharmaceutical company, develops medicines based on its epigenetic regulator program. The company's lead product larsucosterol (DUR-928), an endogenous, orally bioavailable small molecule that is in Phase IIb clinical trial to play a regulatory role in lipid metabolism, stress and inflammatory responses, and cell death and survival to treat alcohol-associated hepatitis, as well as completed Phase Ib clinical trial to treat patients with nonalcoholic steatohepatitis.